US 12,458,634 B2
Stabilized liquid formations containing picosulfate
Alfred Chi-Yeh Liang, Rahway, NJ (US); and Nipul Ghanshyambhai Patel, Avenel, NJ (US)
Assigned to Ferring B.V., Hoofddorp (NL)
Filed by Ferring B.V., Hoofddorp (NL)
Filed on Dec. 17, 2021, as Appl. No. 17/555,277.
Application 17/555,277 is a continuation of application No. 15/643,727, filed on Jul. 7, 2017, abandoned.
Claims priority of provisional application 62/360,188, filed on Jul. 8, 2016.
Prior Publication US 2022/0370427 A1, Nov. 24, 2022
Int. Cl. A61K 31/4402 (2006.01); A61K 9/08 (2006.01); A61K 33/06 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/4402 (2013.01) [A61K 9/08 (2013.01); A61K 33/06 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01)] 15 Claims
 
1. An oral, liquid pharmaceutical composition comprising:
sodium picosulfate,
magnesium oxide,
citric acid,
malic acid, and
an antioxidant selected from potassium metabisulfite and sodium metabisulfite;
wherein the antioxidant is present in the composition at a concentration of from about 0.002 M to about 0.1 M, and
wherein the composition has a pH of from about 4.0 to about 6.5.